Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Flavopiridol

CDK inhibitor
 
ALX-430-161-M005 5 mg 95.00 USD
 
ALX-430-161-M025 25 mg 349.00 USD
Do you need bulk/larger quantities?
 
Potent inhibitor of cyclin-dependent kinases (CDKs). Induces apoptosis in certain tumor cells. Interacts with multidrug resistance protein 1 (MRP1).

Product Details

Alternative Name:Alvocidib, (-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one
 
Formula:C21H20ClNO5
 
MW:401.8
 
Source:Synthetic.
 
CAS:146426-40-6
 
MI:14: 4094
 
Purity:≥97% (HPLC)
 
Identity:Identity determined by 1H-NMR.
 
Appearance:Yellow powder.
 
Solubility:Soluble in chloroform; slightly soluble in water.
 
Shipping:Ambient Temperature
 
Long Term Storage:+4°C
 
Regulatory Status:RUO - Research Use Only
 
430-161
Please mouse over
430-161

Product Literature References

Neutrophil Extracellular Trap Formation Is Independent of De Novo Gene Expression: G. Sollberger, et al.; PLoS One 11, e0157454 (2016), Application(s): Inhibition, Abstract; Full Text
Germline gain-of-function mutations in AFF4 cause a developmental syndrome functionally linking the super elongation complex and cohesin: K. Izumi, et al.; Nat. Genet. 47, 338 (2015), Application(s): Cell Culture, Abstract;
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors: C. Sekine, et al.; J. Immunol. 180, 1954 (2008), Abstract;
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL: T.E. Fandy, et al.; Cancer Chemother. Pharmacol. 60, 313 (2007), Abstract;
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics: A. Pumrery, et al.; Curr. Pharm. Des. 12, 1949 (2006), Abstract;
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells: U. Raju, et al.; Cancer Res. 63, 3263 (2003), Abstract; Full Text
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia: S. Kitada, et al.; Blood 96, 393 (2000), Abstract; Full Text
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials: A.M. Senderowicz; Invest. New Drugs 17, 313 (1999), (Review), Abstract;
Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein: J.B. Schnier, et al.; FEBS Lett. 454, 100 (1999), Abstract;
Potent interaction of flavopiridol with MRP1: J.H. Hooijberg, et al.; Br. J. Cancer 81, 269 (1999), Abstract;
Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells: S. Brüsselbach, et al.; Int. J. Cancer 77, 146 (1998), Abstract;
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53: J.C. Byrd, et al.; Blood 92, 3804 (1998), Abstract; Full Text
Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts: F. Arguello, et al.; Blood 91, 2482 (1998), Abstract; Full Text
Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells: M. Drees, et al.; Clin. Cancer Res. 3, 273 (1997), Abstract; Full Text
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines: A. König, et al.; Blood 90, 4307 (1997), Abstract; Full Text
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells: B.A. Carlson, et al.; Cancer Res. 56, 2973 (1996), Abstract; Full Text
Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells: K.C. Bible & S.H. Kaufmann; Cancer Res. 56, 4856 (1996), Abstract; Full Text
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase: W.F. Jr. De Azevedo, et al.; PNAS 93, 2735 (1996), Abstract; Full Text

Related Literature

Brochures
Comprehensive Tools for Quantifying Cellular Responses to Oxidative Damage
Comprehensive Tools for Quantifying Cellular Responses to Oxidative Damage
Download as PDF

All new literature pieces